LEFKOFSKY ERIC P sold $16.3M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 238,152 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $68.39 ($64.03–$70.58, $16.29M total) across 30 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Aug 28, 2026, 12:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishMed
01

Why it matters

The disclosed sale represents a material reduction in insider ownership, which can influence market perception and short‑term price action.

02

Market read

Insider sell of $16M by the CEO is a notable event for traders monitoring TEM; may prompt short positions or caution.

03

What to watch

Potential upcoming earnings or strategic announcements that may offset sell pressure.

Relevance 6/10Novelty 6/10Timing: post‑market 2026‑08‑25

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Eric Lefkofsky sold 238,152 shares of Tempus AI for $16.3M via a 10b5‑1 plan on 2026‑08‑25.

Expected impact

Possible modest price decline in the near term.

Evidence & confidence

Large insider sale ($16M) by the CEO suggests confidence concerns; however, the sale is pre‑arranged under a 10b5‑1 plan, limiting immediate inference.

Market effects

May weigh on AI‑healthcare sector sentiment as a high‑profile founder exits shares.

Limited to U.S. market where TEM trades.

Low global impact; primarily relevant to investors in Tempus AI.

Counterpoint

The sale is pre‑arranged; could be neutral or even a liquidity event without negative outlook.

Key entities

  • Tempus AI, Inc.

    AI‑driven healthcare data company (NASDAQ: TEM).

  • Eric Lefkofsky

    CEO, Chairman, and 10% owner of Tempus AI.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.